Advertisements
Thursday, February 21, 2019
No Result
View All Result
Middle East Affairs
  • Home
  • News
  • Opinions
  • In Depth
  • Arab World
  • Palestinian & Israeli Affairs
  • Business
  • Sports
    • Football
    • Basketball
    • Tennis
    • Other
  • Home
  • News
  • Opinions
  • In Depth
  • Arab World
  • Palestinian & Israeli Affairs
  • Business
  • Sports
    • Football
    • Basketball
    • Tennis
    • Other
No Result
View All Result
Middle East Affairs
No Result
View All Result

The U.S. Food and Drug Administration excluded three drug substances

Mohammed Alkaisi by Mohammed Alkaisi
August 28, 2018
in News
0
FILE PHOTO: A view shows the U.S. Food and Drug Administration (FDA) headquarters in Silver Spring, Maryland August 14, 2012. REUTERS/Jason ReedREUTERS/File Photo

FILE PHOTO: A view shows the U.S. Food and Drug Administration (FDA) headquarters in Silver Spring, Maryland August 14, 2012. REUTERS/Jason ReedREUTERS/File Photo

The U.S. Food and Drug Administration on Monday proposed excluding three substances from a list of ingredients that could be used to manufacture compounded medications in bulk for use by hospitals and doctors’ offices.

The action was the first time the regulator has moved to exclude any substance from a list of ingredients that may be used to produce in bulk compounded medications that do not need to go through the agency’s safety approval process.

Those substances included vasopressin, the active ingredient in Endo International Plc’s blood pressure drug Vasostrict, which has been the subject of a lawsuit by the company targeting how the FDA regulates drug compounding. Shares of Endo jumped 5 percent.

The other two substances are bumetanide and nicardipine hydrochloride, which the regulator said are also ingredients of one or more FDA-approved drug products.

On Aug. 13, Buffalo, New-York-based pharmaceutical company Athenex Inc said it had begun selling a compounded formulation of vasopressin that could compete with Vasostrict. Its stock price fell 1.43 percent to $14.45 on the news of the FDA’s proposal.

Endo, which reported $399.9 million in Vasostrict sales in 2017, said it was “extremely pleased” with the FDA’s proposal. Its stock price mid-Monday was $16.33, up 5.08 percent.

Athenex did not respond to requests for comment.

Compounded medications are custom-made medications that traditionally were formulated by pharmacies for specific patients.

By 2012, the practice had mushroomed, with some pharmacies selling thousands of doses of regularly used mixtures for physicians to keep for future use.

That year, there was a fungal meningitis outbreak caused by tainted steroids made by a compounding pharmacy. That prompted Congress in 2013 to pass a law aimed at bringing more compounding pharmacies, traditionally overseen by states, under FDA oversight.

The law, the Drug Quality and Security Act, created a category of “outsourcing facilities” that could register with the FDA and sell products in bulk while following federal manufacturing standards.

The FDA was also required to determine that bulk compounding using a drug substance was necessary to satisfy an unmet “clinical need” and include those substances on a list.

Under an interim policy, it allowed use of substances with no major safety issues, that compounders could nominate for eventual inclusion on the list.

Endo sued in October, claiming the FDA was authorizing the compounding of hundreds of drugs without proper evaluation, including “essentially a copy” of Vasostrict by another company. (Reuters)

Read more >> EU DRUGS AGENCY IS TO SCALE BACK OPERATIONS FURTHER AS IT COPES WITH HIGHER THAN EXPECTED STAFF LOSSES

Advertisements

Share this:

  • Twitter
  • Facebook

Like this:

Like Loading...
Tags: drugdrugsFDAVasostrict
Previous Post

India has asked WhatsApp to response on petition alleging it breaches law

Next Post

Right-wing supporters protest after a German man was stabbed in Chemnitz

Next Post
Right-wing supporters protest after a German man was stabbed last weekend in Chemnitz, Germany, August 27, 2018. REUTERS/Matthias Rietschel

Right-wing supporters protest after a German man was stabbed in Chemnitz

Leave a Reply Cancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

No Result
View All Result

RECENT NEWS

A general view of the Saudi Arabian Military Industries (SAMI) exhibit is seen during the International Defence Exhibition & Conference (IDEX) in Abu Dhabi, United Arab Emirates February 17, 2019. REUTERS/Christopher Pike

Saudi Arabia signs warship construction deal with France’s Naval Group

February 17, 2019
A handout picture made available by the Iranian Army office reportedly shows a Sayad missile fired from the Talash missile system during an air defence drill at an undisclosed location in Iran on November 5, 2018. (File/AFP)

Iran presents new Fateh submarine armed with cruise missile – TV

February 17, 2019
Lebanon's Finance Minister Raya Haffar al-Hassan speaks during a news conference in her office in Beirut April 15, 2010.    REUTERS/Jamal Saidi

Lebanese women hail first female Arab interior minister

February 17, 2019

FOLLOW US

Facebook Twitter Instagram




  • Home
  • News
  • Opinions
  • In Depth
  • Arab World
  • Palestinian & Israeli Affairs
  • Business
  • Sports

© 2018 Middle East Affairs. Our email address is info@middleeataffairs.net

No Result
View All Result
  • Home
  • News
  • Opinions
  • In Depth
  • Arab World
  • Palestinian & Israeli Affairs
  • Business
  • Sports
    • Football
    • Basketball
    • Tennis
    • Other

© 2018 Middle East Affairs. Our email address is info@middleeataffairs.net

%d bloggers like this: